Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

(2021) Max Jan et al.   Science Translational Medicine

CAR T cells in solid tumors: challenges and opportunities

(2021) Faroogh Marofi et al.   Stem Cell Research & Therapy

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma

(2021) Darel Martínez Bedoya et al.   Frontiers in Immunology

Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment

(2021) Guangna Liu et al.   Cellular & Molecular Immunology

Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

(2021) Zowi R. Huinen et al.   Nature Reviews Clinical Oncology

Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma

(2021) Kamonlapat Supimon et al.   Scientific Reports

Anti-tumor effects of vascular endothelial growth factor/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells

(2021) Haiyan Xing et al.   CYTOTHERAPY

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding

(2021) Evripidis Lanitis et al.   Journal for ImmunoTherapy of Cancer

Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead

(2021) Kedar Kirtane et al.   Journal for ImmunoTherapy of Cancer

T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

(2021) Stefanie Lesch et al.   Nature Biomedical Engineering

An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates

(2020) Jermaine Goveia et al.   CANCER CELL

Immune checkpoint signaling and cancer immunotherapy

(2020) Xing He et al.   CELL RESEARCH

VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma

(2020) Alexander Englisch et al.   PEDIATRIC BLOOD & CANCER

A conformation-specific ON-switch for controlling CAR T cells with an orally available drug

(2020) Charlotte U. Zajc et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Driving CARs with alternative navigation tools – the potential of engineered binding scaffolds

(2020) Charlotte U. Zajc et al.   FEBS Journal

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment

(2020) Judy R. van Beijnum et al.   Cancers

Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors

(2020) Marjolein M.G. Kes et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Antitumor effects of CAR T cells redirected to the EDB splice variant of fibronectin

(2020) Jessica Wagner et al.   Cancer Immunology Research

T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy

(2019) Fatemeh Hajari Taheri et al.   IUBMB LIFE

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells

(2019) Esther Drent et al.   CLINICAL CANCER RESEARCH

3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

(2019) Theresa E Schnalzger et al.   EMBO JOURNAL

Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma

(2019) Xiuqi Wu et al.   MOLECULAR THERAPY

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

(2019) Yushu Joy Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies

(2019) Lynsey M. Whilding et al.   Cancers

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

(2019) Stefan Stoiber et al.   Cells

Modulation of chimeric antigen receptor surface expression by a small molecule switch

(2019) Alexandre Juillerat et al.   BMC BIOTECHNOLOGY

CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models

(2019) Huizhong Li et al.   JOURNAL OF IMMUNOTHERAPY

The tumor vasculature an attractive CAR T cell target in solid tumors

(2019) Parvin Akbari et al.   ANGIOGENESIS

The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors

(2019) Changwen Deng et al.   MOLECULAR THERAPY

TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

(2019) Kristina Petrovic et al.   PLoS One

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

(2018) Nan Chen et al.   CURRENT OPINION IN IMMUNOLOGY

Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide

(2018) Erhao Zhang et al.   Journal of Hematology & Oncology

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

(2018) Esther Drent et al.   PLoS One

VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells

(2018) Sergey V. Kulemzin et al.   Oncotarget

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager

(2018) Anna Wing et al.   Cancer Immunology Research

Targeting VEGF/VEGFR to Modulate Antitumor Immunity

(2018) Ju Yang et al.   Frontiers in Immunology

Checkpoint blockade reverses anergy in IL13Rα2 humanized scFv based CAR T cells to treat murine and canine gliomas.

(2018) Yibo Yin et al.   Molecular Therapy-Oncolytics

Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors

(2018) Yong Gu Lee et al.   CANCER RESEARCH

Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia

(2018) Chun-Hui Jin et al.   EBioMedicine

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers

(2018) Claudia Rossig et al.   Frontiers in Oncology

Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells

(2017) Elizabeth Siegler et al.   HUMAN GENE THERAPY

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation

(2017) Josefa A. Rodríguez   Oncology Letters

High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

(2017) Sarah A. Richman et al.   Cancer Immunology Research

Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model

(2017) Paola Bocca et al.   OncoImmunology

Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).

(2017) Susan F. Slovin et al.   JOURNAL OF CLINICAL ONCOLOGY

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Role of the tumor stroma in resistance to anti-angiogenic therapy

(2016) Elisabeth J.M. Huijbers et al.   DRUG RESISTANCE UPDATES

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response

(2016) Richard P. Junghans et al.   PROSTATE

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

(2015) H. G. Caruso et al.   CANCER RESEARCH

Targeting the tumor vasculature to enhance T cell activity

(2015) Evripidis Lanitis et al.   CURRENT OPINION IN IMMUNOLOGY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

(2015) De-Gang Song et al.   Oncotarget

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

(2014) George C. Prendergast et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Trafficking of T Cells into Tumors

(2014) C. Y. Slaney et al.   CANCER RESEARCH

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding the structural dynamics of TCR-pMHC interactions

(2014) Itamar Kass et al.   TRENDS IN IMMUNOLOGY

T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression

(2014) S. P. Santoro et al.   Cancer Immunology Research

Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice

(2013) D. Chinnasamy et al.   CANCER RESEARCH

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency

(2013) W Wang et al.   GENE THERAPY

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

(2013) Markus Chmielewski et al.   IMMUNOLOGICAL REVIEWS

Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery

(2013) Xinping Fu et al.   INTERNATIONAL JOURNAL OF CANCER

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

(2013) Meenakshi Hegde et al.   MOLECULAR THERAPY

Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma

(2013) Sunitha Kakarla et al.   MOLECULAR THERAPY

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

(2013) E. Lanitis et al.   Cancer Immunology Research

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

(2013) Zakaria Grada et al.   Molecular Therapy-Nucleic Acids

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells

(2013) Markus Chmielewski et al.   Frontiers in Immunology

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

(2012) A. W. Griffioen et al.   CLINICAL CANCER RESEARCH

Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

(2012) K. Tamada et al.   CLINICAL CANCER RESEARCH

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts

(2012) L J A C Hawinkels et al.   ONCOGENE

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Vaccination against the extra domain-B of fibronectin as a novel tumor therapy

(2010) Elisabeth J. M. Huijbers et al.   FASEB JOURNAL

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY